mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line
Status:
Completed
Trial end date:
2020-07-25
Target enrollment:
Participant gender:
Summary
In second line with advanced or recurrent biliary tract cancer refractory to first line
gemcitabine plus cisplatin, efficacy of mFOLFOX vs. mFOLFIRI will be evaluated at randomized
phase 2 trial.